An observational study in Excessive Gestational Weight Gain, sponsored by Cumhuriyet University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Cumhuriyet University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This observational cross-sectional study aims to investigate the association of excessive gestational weight gain with intestinal barrier function, metabolic endotoxemia, systemic inflammation, vitamin D/VDR signaling, and insulin resistance in pregnant women with normal pre-pregnancy body mass index (BMI).
The study includes 80 women with singleton pregnancies at ≥37 weeks of gestation, divided into two groups according to the 2009 Institute of Medicine (IOM) gestational weight gain recommendations: excessive gestational weight gain (n=40) and recommended gestational weight gain (n=40).
Serum levels of zonulin, intestinal fatty acid-binding protein (I-FABP), glucagon-like peptide-2 (GLP-2), lipopolysaccharide-binding protein (LBP), soluble CD14 (sCD14), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), vitamin D receptor (VDR), and 25-hydroxyvitamin D [25(OH)D] will be evaluated. The findings may help identify biomarkers associated with maternal metabolic risk.
This observational, cross-sectional study is conducted at the Department of Obstetrics and Gynecology, Sivas Cumhuriyet University Faculty of Medicine Hospital, Türkiye. The study includes 80 pregnant women with normal pre-pregnancy BMI (18.5-24.9 kg/m²), singleton pregnancies at ≥37 weeks of gestation, and no known metabolic diseases.
Participants are classified into two groups based on gestational weight gain according to the 2009 Institute of Medicine (IOM) recommendations:
Maternal demographic, anthropometric, and routine biochemical data are recorded. Blood samples collected from participants are used to evaluate intestinal barrier integrity, metabolic endotoxemia, systemic inflammation, vitamin D/VDR signaling, and insulin resistance.
Serum concentrations of zonulin, I-FABP, and GLP-2 are assessed as intestinal barrier-related biomarkers. LBP and sCD14 are measured as markers associated with metabolic endotoxemia, while TNF-α, IL-6, and hs-CRP are evaluated as inflammatory biomarkers. VDR and 25(OH)D levels are assessed to investigate the potential role of vitamin D signaling in maternal metabolic alterations. Biomarker measurements are performed using commercially available ELISA kits.
Routine biochemical parameters and indicators of insulin resistance are also evaluated. Differences between the two groups and associations among biomarkers, gestational weight gain, and metabolic parameters are analyzed using appropriate statistical methods.
The study aims to investigate whether excessive gestational weight gain is associated with alterations in intestinal barrier-related biomarkers, increased metabolic endotoxemia, systemic inflammation, and insulin resistance, and whether the vitamin D/VDR axis may play a modulatory role in these relationships.
The findings are expected to contribute to understanding the biological mechanisms associated with excessive gestational weight gain and to identifying potential biomarkers of maternal metabolic risk.
135 studies on the registry are indexed under Gestational Weight Gain; 24 are open to participants now.
This study's enrollment of 80 is below the median of 400 across 23 observational studies indexed under Gestational Weight Gain.
Browse Gestational Weight Gain studies →Cumhuriyet University is the lead sponsor of 135 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of 80 pregnant women with normal pre-pregnancy BMI (18.5-24.9 kg/m²), singleton pregnancies at ≥37 weeks of gestation, and no known metabolic diseases, followed at Sivas Cumhuriyet University Faculty of Medicine Hospital. Participants are classified into two groups according to the 2009 IOM gestational weight gain recommendations: excessive gestational weight gain (n=40) and recommended gestational weight gain (n=40).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pregnant women with normal pre-pregnancy BMI (18.5-24.9 kg/m²) and gestational weight gain exceeding the 2009 IOM recommendations (n=40).
Pregnant women with normal pre-pregnancy BMI (18.5-24.9 kg/m²) and gestational weight gain within the 2009 IOM recommended range (n=40).
Serum Zonulin Level
Serum zonulin concentrations measured using a commercially available ELISA kit and compared between the excessive and recommended gestational weight gain groups
Time frame: At enrollment (≥37 weeks of gestation)
Serum I-FABP Level
Serum intestinal fatty acid-binding protein (I-FABP) concentrations measured using a commercially available ELISA kit and compared between the two gestational weight gain groups.
Time frame: At enrollment (≥37 weeks of gestation)
Serum GLP-2 Level
Serum glucagon-like peptide-2 (GLP-2) concentrations measured using a commercially available ELISA kit and compared between the two gestational weight gain groups.
Time frame: At enrollment (≥37 weeks of gestation)
Serum LBP Level
Serum lipopolysaccharide-binding protein (LBP) concentration measured using a commercially available ELISA kit and compared between the excessive and recommended gestational weight gain groups.
Time frame: At enrollment (≥37 weeks of gestation)
Serum sCD14 Level
Serum soluble CD14 (sCD14) concentration measured using a commercially available ELISA kit and compared between the excessive and recommended gestational weight gain groups.
Time frame: At enrollment (≥37 weeks of gestation)
Serum TNF-alpha Level
Serum tumor necrosis factor-alpha (TNF-α) concentration measured using a commercially available ELISA kit and compared between the excessive and recommended gestational weight gain groups.
Time frame: At enrollment (≥37 weeks of gestation)
Serum IL-6 Level
Serum interleukin-6 (IL-6) concentration measured using a commercially available ELISA kit and compared between the excessive and recommended gestational weight gain groups.
Time frame: At enrollment (≥37 weeks of gestation)
Serum hs-CRP Level
Serum high-sensitivity C-reactive protein (hs-CRP) concentration measured using a commercially available ELISA kit and compared between the excessive and recommended gestational weight gain groups.
Time frame: At enrollment (≥37 weeks of gestation)
Serum Vitamin D Receptor Level
Serum vitamin D receptor (VDR) concentration measured using a commercially available ELISA kit and compared between the excessive and recommended gestational weight gain groups.
Time frame: At enrollment (≥37 weeks of gestation)
Serum 25-Hydroxyvitamin D Level
Serum 25-hydroxyvitamin D \[25(OH)D\] concentration measured using a commercially available ELISA kit and compared between the excessive and recommended gestational weight gain groups.
Time frame: At enrollment (≥37 weeks of gestation)
Fasting Blood Glucose Level
Fasting blood glucose concentration measured using routine biochemical laboratory methods and compared between the excessive and recommended gestational weight gain groups.
Time frame: At enrollment (≥37 weeks of gestation)
Fasting Serum Insulin Level
Fasting serum insulin concentration measured using routine laboratory methods and compared between the excessive and recommended gestational weight gain groups.
Time frame: At enrollment (≥37 weeks of gestation)
HOMA-IR Index
Insulin resistance assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated as fasting glucose (mg/dL) multiplied by fasting insulin (µIU/mL) divided by 405. HOMA-IR values will be compared between the excessive and recommended gestational weight gain groups.
Time frame: At enrollment (≥37 weeks of gestation)
Plan to share: No — After complatet the study i will be agree to share.
No publications or documents are linked to this record.
Ran from Apr 2026 to primary completion in Nov 2026, 6 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.